News

Belzutifan Plus Cabozantinib Shows Promise in Previously Treated Clear Cell Renal Cell Carcinoma

04/12/2023

In a phase 2 trial, belzutifan plus cabozantinib showed promising antitumor activity among patients with clear cell renal cell carcinoma who had received prior PD-1/PD-L1 inhibition.

In a phase 2 trial, belzutifan...

04/12/2023

Oncology

Conference Coverage

Radiolabeled 89Zr-DFO-girentuximab PET/CT Imaging Accurately Identifies Clear Cell Renal Cell Carcinoma

02/22/2023

Allison Casey ;

According to phase 3 results presented at the 2023 ASCO GU Cancers Symposium, radiolabeled 89Zr-DFO-girentuximab (TLX250-CDx) PET/CT was able to accurately identify clear cell renal cell carcinoma.

According to phase 3 results...

02/22/2023

Oncology

Conference Coverage

Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma

02/21/2023

Allison Casey ;

According to 3-year follow-up data presented at the 2023 ASCO GU Symposium, nivolumab plus cabozantinib continues to demonstrate benefits in survival and response for patients with advanced renal cell carcinoma, compared with sunitinib.

According to 3-year follow-up...

02/21/2023

Oncology

News

Bevacizumab Plus Sunitinib for Patients With Advanced Renal Cell Carcinoma

01/26/2023

Allison Casey ;

In a phase 1/2 study, the addition of bevacizumab to a sunitinib on/off regimen demonstrated anti-tumor activity for patients with advanced renal cell carcinoma.

In a phase 1/2 study, the...

01/26/2023

Oncology

News

Nivolumab, Ipilimumab, and Cabozantinib Triplet Therapy Demonstrates Clinical Activity for Patients With Advanced Renal Cell Carcinoma

12/01/2022

Allison Casey ;

According to results from a discontinued arm of a phase 3 trial, the immunotherapy triplet regimen of nivolumab, ipilimumab, and cabozantinib demonstrated clinical activity in previously untreated patients with advanced renal cell carcinoma.

According to results from a...

12/01/2022

Oncology

News

Frontline Axitinib Plus Pembrolizumab vs Ipilimumab Plus Nivolumab for Metastatic Renal Cell Carcinoma

10/31/2022

Findings from a comparative effectiveness analysis show no statistically significant difference in survival outcomes between axitinib plus pembrolizumab vs ipilimumab plus nivolumab for the frontline treatment of patients with metastatic...

Findings from a comparative...

10/31/2022

Oncology

News

Sapanisertib With or Without TAK-117 vs Everolimus for Clear Cell Renal Cell Carcinoma

10/27/2022

In a phase 2 study, sapanisertib with or without TAK-177 demonstrated lower tolerability with no improvement in efficacy vs everolimus for patients with advanced clear cell renal cell carcinoma.

In a phase 2 study, sapanisertib...

10/27/2022

Oncology

Axel Bex, MD, Netherlands Cancer Institute

Videos

Adjuvant Atezolizumab vs Placebo Following Nephrectomy for Patients With Renal Cell Carcinoma at Increased Risk of Recurrence

10/19/2022

Axel Bex, MD, reviews results from the phase 3 IMmotion010 trial showing no benefit to clinical outcomes with adjuvant atezolizumab vs placebo following nephrectomy for patients with renal cell carcinoma and an increased risk of recurrence.

Axel Bex, MD, reviews results...

10/19/2022

Oncology

News

Adjuvant Pembrolizumab Demonstrates Durable Survival Benefit for Post-Nephrectomy Patients With Clear Cell Renal Cell Carcinoma

09/30/2022

Allison Casey ;

Follow-up analysis of the phase 3 KEYNOTE-564 trial demonstrates a durable benefit from pembrolizumab in disease-free survival for patients who had undergone nephrectomy for clear cell renal cell carcinoma.

Follow-up analysis of the phase...

09/30/2022

Oncology

Conference Coverage

Perioperative Nivolumab Shows No Benefit to Recurrence-Free Survival for Patients With Renal Cell Carcinoma

09/10/2022

Allison Casey ;

Perioperative nivolumab did not improve recurrence-free survival for patients with renal cell carcinoma at high risk for recurrence, according to phase 3 study results presented at the 2022 ESMO Congress.

Perioperative nivolumab did not...

09/10/2022

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology